Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTR20191888 YPEG-rhG-CSF (Paijin) vs G-CSF/PEG-G-CSF for chemotherapy-induced neutropenia
CTR20191888Phase 3Completed
- Sponsor
- Tebao Biotech
- Start
- Jun 2020
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telpegfilgrastim in breast cancer, non-small cell lung cancer (NSCLC), chemotherapy-induced neutropenia (CIN), febrile neutropenia (FN), sponsored by Tebao Biotech. Started Jun 2020; status: completed.
02
Drugs
telpegfilgrastim
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on CTR20191888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191888.